Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer

Shuhei Mayanagi, Yasuhiro Tsubosa, Katsuhiro Omae, Masahiro Niihara, Tsuneyuki Uchida, Takahiro Tsushima, Tomoya Yokota, Hiroshi Sato, Tateaki Naito, Hirofumi Yasui

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery. Methods: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4 months after surgery as well as the postoperative recurrence and overall survival (OS). Results: Of the 66 patients, 39 (59%) showed a skeletal muscle decrease from baseline to 4 months after esophagectomy. The change in the skeletal muscle index from baseline to 4 months after surgery was −1.2 cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p = 0.029), pathologic stage (HR 5.73; p < 0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p = 0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p < 0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p = 0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival. Conclusions: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalAnnals of Surgical Oncology
DOIs
Publication statusAccepted/In press - 2017 Aug 31
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Skeletal Muscle
Thorax
Drug Therapy
Survival
Esophagectomy
Recurrence
Lumbar Vertebrae
Carcinoma
Muscles

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. / Mayanagi, Shuhei; Tsubosa, Yasuhiro; Omae, Katsuhiro; Niihara, Masahiro; Uchida, Tsuneyuki; Tsushima, Takahiro; Yokota, Tomoya; Sato, Hiroshi; Naito, Tateaki; Yasui, Hirofumi.

In: Annals of Surgical Oncology, 31.08.2017, p. 1-7.

Research output: Contribution to journalArticle

Mayanagi, Shuhei ; Tsubosa, Yasuhiro ; Omae, Katsuhiro ; Niihara, Masahiro ; Uchida, Tsuneyuki ; Tsushima, Takahiro ; Yokota, Tomoya ; Sato, Hiroshi ; Naito, Tateaki ; Yasui, Hirofumi. / Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. In: Annals of Surgical Oncology. 2017 ; pp. 1-7.
@article{b199e2e032f54aca83ec4923721e1e0b,
title = "Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer",
abstract = "Background: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery. Methods: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4 months after surgery as well as the postoperative recurrence and overall survival (OS). Results: Of the 66 patients, 39 (59{\%}) showed a skeletal muscle decrease from baseline to 4 months after esophagectomy. The change in the skeletal muscle index from baseline to 4 months after surgery was −1.2 cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p = 0.029), pathologic stage (HR 5.73; p < 0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p = 0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p < 0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p = 0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival. Conclusions: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.",
author = "Shuhei Mayanagi and Yasuhiro Tsubosa and Katsuhiro Omae and Masahiro Niihara and Tsuneyuki Uchida and Takahiro Tsushima and Tomoya Yokota and Hiroshi Sato and Tateaki Naito and Hirofumi Yasui",
year = "2017",
month = "8",
day = "31",
doi = "10.1245/s10434-017-6020-2",
language = "English",
pages = "1--7",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer

AU - Mayanagi, Shuhei

AU - Tsubosa, Yasuhiro

AU - Omae, Katsuhiro

AU - Niihara, Masahiro

AU - Uchida, Tsuneyuki

AU - Tsushima, Takahiro

AU - Yokota, Tomoya

AU - Sato, Hiroshi

AU - Naito, Tateaki

AU - Yasui, Hirofumi

PY - 2017/8/31

Y1 - 2017/8/31

N2 - Background: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery. Methods: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4 months after surgery as well as the postoperative recurrence and overall survival (OS). Results: Of the 66 patients, 39 (59%) showed a skeletal muscle decrease from baseline to 4 months after esophagectomy. The change in the skeletal muscle index from baseline to 4 months after surgery was −1.2 cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p = 0.029), pathologic stage (HR 5.73; p < 0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p = 0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p < 0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p = 0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival. Conclusions: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.

AB - Background: Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely affects prognosis. This study aimed to determine the relation between skeletal muscle change and survival for patients with advanced esophageal cancer who underwent neoadjuvant chemotherapy followed by surgery. Methods: This study retrospectively analyzed 66 patients with thoracic esophageal cancer who had undergone neoadjuvant chemotherapy followed by esophagectomy. The study investigated the correlation between the change in the total muscle cross-sectional area at the third lumbar vertebra before and 4 months after surgery as well as the postoperative recurrence and overall survival (OS). Results: Of the 66 patients, 39 (59%) showed a skeletal muscle decrease from baseline to 4 months after esophagectomy. The change in the skeletal muscle index from baseline to 4 months after surgery was −1.2 cm2/m2. Multivariable analysis showed that nonsquamous cell carcinoma subtype (hazard ratio [HR] 2.57; p = 0.029), pathologic stage (HR 5.73; p < 0.01), and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.16; p = 0.015) were the independent prognostic factors associated with worse OS. Additionally, pathologic stage (HR 6.03; p < 0.01) and skeletal muscle wasting (HR per 1 unit decrease in skeletal muscle index, 1.11; p = 0.048) also were found to be independent prognostic factors associated with worse recurrence-free survival. Conclusions: The study findings suggest that skeletal muscle wasting from baseline has a negative impact on cancer recurrence and survival.

UR - http://www.scopus.com/inward/record.url?scp=85028753331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028753331&partnerID=8YFLogxK

U2 - 10.1245/s10434-017-6020-2

DO - 10.1245/s10434-017-6020-2

M3 - Article

C2 - 28861809

AN - SCOPUS:85028753331

SP - 1

EP - 7

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -